Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.70+0.07 (+1.24%)
Close on Nov 17, 2026Market cap $740.91MP/E –Yield –
Cytek Biosciences total assets
Total assets on the balance sheet at the end of each period.
Cytek Biosciences's total assets was $446.93M at Jun 30, 2026. For fiscal 2025 it was $461.54M, down 7.6% from the year before. The highest annual figure on record is $519.48M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $461.54M | -7.6% |
| FY2024 | Dec 31, 2024 | $499.50M | +1.0% |
| FY2023 | Dec 31, 2023 | $494.46M | -4.8% |
| FY2022 | Dec 31, 2022 | $519.48M | +12.1% |
| FY2021 | Dec 31, 2021 | $463.31M | +110.6% |
| FY2020 | Dec 31, 2020 | $219.98M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $446.93M | -9.4% |
| Q1 FY2026 | Mar 31, 2026 | $449.11M | -6.9% |
| Q4 FY2025 | Dec 31, 2025 | $461.54M | -7.6% |
| Q3 FY2025 | Sep 30, 2025 | $494.92M | +0.8% |
| Q2 FY2025 | Jun 30, 2025 | $493.32M | +2.0% |
| Q1 FY2025 | Mar 31, 2025 | $482.60M | -1.9% |
| Q4 FY2024 | Dec 31, 2024 | $499.50M | +1.0% |
| Q3 FY2024 | Sep 30, 2024 | $491.23M | -5.4% |
| Q2 FY2024 | Jun 30, 2024 | $483.73M | -7.9% |
| Q1 FY2024 | Mar 31, 2024 | $492.07M | -6.2% |
| Q4 FY2023 | Dec 31, 2023 | $494.46M | -4.8% |
| Q3 FY2023 | Sep 30, 2023 | $519.43M | +4.0% |
| Q2 FY2023 | Jun 30, 2023 | $525.05M | +6.5% |
| Q1 FY2023 | Mar 31, 2023 | $524.58M | +8.0% |
| Q4 FY2022 | Dec 31, 2022 | $519.48M | +12.1% |
| Q3 FY2022 | Sep 30, 2022 | $499.30M | +9.9% |
| Q2 FY2022 | Jun 30, 2022 | $492.82M | +114.0% |
| Q1 FY2022 | Mar 31, 2022 | $485.88M | +120.9% |
| Q4 FY2021 | Dec 31, 2021 | $463.31M | – |
| Q3 FY2021 | Sep 30, 2021 | $454.32M | – |
| Q2 FY2021 | Jun 30, 2021 | $230.28M | – |
| Q4 FY2020 | Dec 31, 2020 | $219.98M | – |
See a number that looks wrong?